MIMETAS’ Post

Read about our collaborative study with Amsterdam UMC on a multicellular human 3D Blood-Brain Barrier (BBB) on-a-chip model comprising human brain microvascular endothelial cells (HBMECs). This model provides critical insights into barrier disruption, endothelial inflammation, and T cell migration under neuroinflammatory conditions, mimicking diseases like multiple sclerosis and stroke. The BBB-on-a-chip shows great potential for studying immune cell infiltration and evaluating new therapeutic strategies. Notably, the findings indicate that T cell migration is reduced by Natalizumab, a treatment for multiple sclerosis. This research marks a significant advancement in understanding neuroinflammation and developing targeted therapies for neurological disorders. 🔗 Read the full article here: https://lnkd.in/eqE9KdJW #Neuroscience #Research #BloodBrainBarrier #OrganOnAChip #Neuroinflammation

Check out our brand new app note: High-Throughput Toxicity Assessment in OrganoReady® Blood Vessel HUVEC! Snakebites are a major global health issue, affecting millions either fatally or leaving them with permanent injury by disrupting blood vessels. In this app note, we describe an assay to assess vascular toxicity from various snake venoms in the OrganoReady® Blood Vessel HUVEC 3-lane 64 using a multimode microplate reader. 🔬 Key Highlights: - 64 ready-to-use 3D human blood vessels in the OrganoPlate® - Image-based protocols for real-time monitoring of endothelial barrier function, cell viability, and morphological changes - High-throughput assessment of vascular toxicity and inflammation 🔗 Read the app note: https://lnkd.in/eu6xYdSr #SnakebiteResearch #ToxicityAssessment #BiotechInnovation

We're proud to be contributing to Project SECRET - a consortium focused on exploring the therapeutic potential of perinatal cell SECRETomes!

Do you want to be the first to hear about our latest 3D tissue models, service/product launches, and new publications and resources? 📩 Our newsletter is your gateway to exclusive insights and developments - delivered directly to you! By subscribing, you'll get: 🔬 The latest research and developments from us and our collaborators 📚 New publications & resources 🛠️ New service & product announcements 📅 Invitations to upcoming webinars and events Stay informed and connected with the most advanced innovations in the field of human 3D tissue disease modeling. Subscribe to our newsletter and never miss an update: https://lnkd.in/eBXdpksJ #Newsletter #3DTissueModels #ScienceandInnovation #Biotech

One of our latest webinars is now available on demand! The webinar, “Modelling ADC- and Chemotherapy-Induced Peripheral Neuropathy-on-a-Chip" features Catherine Rodger, PhD (AstraZeneca) and Xandor Spijkers (MIMETAS). 🔍 Key discussion topics include: - Insights into comprehensive 3D in vitro modeling of nerve damage induced by chemotherapeutics like MTIs. - The utilization of our developed model to better investigate the toxicity of ADCs. - The benefits of partnering with MIMETAS in your drug discovery efforts, aimed at mitigating toxic side-effects and achieving better future treatments. Watch it now: https://lnkd.in/gjStCsb8 #Webinar #DrugDiscovery #PeripheralNeuropathy #ToxicityResearch

We're delighted to announce that MIMETAS has contributed vital human organ-on-chip data to support an Investigational New Drug (IND) application by argenx. This preclinical collaboration investigated the effects of a novel candidate in a human in vitro disease assay in MIMETAS’ OrganoPlate platform. The results contributed to the IND application, representing a significant milestone for both MIMETAS and argenx. This aligns with the 2022 FDA Modernization Act 2.0, emphasizing the importance of advanced in vitro models for drug safety and effectiveness. “By embracing advanced human in vitro models over traditional methods like 2D cell culture and animal models, we can bridge a critical gap towards advancing new therapies,” says our CEO, Jos Joore. 🔗 Read the press release: https://lnkd.in/e-yaPQS6 #DrugDiscovery #InnovativeScience #IND #FDA #Pharma

Are you looking to elevate your toxicity research? At MIMETAS, we advance your compound profiling and screening through complex, human-relevant assays for high-throughput toxicity assessments. Our 3D human tissue models are developed to provide you with accurate, reliable, and actionable data, supporting the development of more effective therapies. 💡 Swipe through to get inspired by some of our toxicity applications and offerings. Discover how MIMETAS can support your specific preclinical research needs: https://lnkd.in/ewYbgQ5c #ToxicityResearch #CompoundProfiling #HighThroughputScreening #OrganOnAChip

Snapshots from Europe's largest neuroscience congress, Federation of European Neuroscience Societies - FENS Forum 2024, where cutting-edge research and innovation in neuroscience take center stage. Our Director of Biology Services, Nienke Wevers, had the pleasure of presenting our latest breakthroughs to an enthusiastic audience. 📊 We showcased two insightful posters: - "Blood-Brain Barrier On-A-Chip To Study Compound-Induced Disruption" - "Human BBB-On-A-Chip Reveals Barrier Disruption, Endothelial Inflammation, And T Cell Migration Under Neuroinflammatory Conditions" Nienke's presentations sparked engaging discussions on these critical areas of research, highlighting the advancements MIMETAS is making in understanding the complexities of the blood-brain barrier and neuroinflammation. 📥 Interested in diving deeper into our findings? Download our BBB app note here: https://lnkd.in/eReeHJQX #FENS2024 #Neuroscience #Research #BloodBrainBarrier #Neuroinflammation